Qiagen N.V. (QGEN)
$
47.85
+0.32 (0.67%)
Key metrics
Financial statements
Free cash flow per share
2.3037
Market cap
10.3 Billion
Price to sales ratio
5.1391
Debt to equity
0.4133
Current ratio
3.3715
Income quality
7.2613
Average inventory
280.3 Million
ROE
0.0269
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
QIAGEN N.V. offers comprehensive sample to insight solutions that facilitate the transformation of biological materials into valuable molecular insights globally. The company provides a range of primary sample technology consumables, including nucleic acid stabilization and purification kits tailored for primary sample materials. It supports both manual and automated processing for various applications such as genotyping, gene expression analysis, and the study of viral and bacterial samples, utilizing advanced technologies like silica membranes and magnetic beads. Additionally, QIAGEN supplies secondary sample technology consumables that include kits and components for nucleic acid purification from secondary samples. The company's product offerings extend to instruments for nucleic acid purification, various accessories, and specialized assays including interferon-gamma release assays for TB testing, post-transplant testing assays, and viral load monitoring. QIAGEN also offers prenatal testing solutions, assays for detecting sexually transmitted diseases and HPV, as well as genomic variant analysis methods that identify mutations, insertions, deletions, and fusions. The sample to insight instruments feature one-step molecular analyses designed for complex syndromes and integrated PCR testing. The company provides a multitude of PCR consumables, including quantitative PCR and reverse transcription kits furthering analysis in areas like gene expression and regulation. Moreover, QIAGEN caters to human identification and forensics with STR assays, alongside food contamination testing. Its PCR instrument line includes innovative digital PCR solutions and tailored OEM consumables. Additionally, the company provides predefined and custom NGS gene panels, library preparation kits, and services for whole genome amplification, along with various bioinformatics solutions and custom laboratory services. Recently, the company reported selling, general, and administrative expenses of $564,361,000.00 indicating its operational overhead costs. Meanwhile, it recorded a net income of $83,591,000.00 which reflects its profitability. This performance is supported by an income before tax ratio of 0.06 demonstrating a solid pre-tax margin. The earnings per share (EPS) is reported at $0.37 highlighting the company's profitability on a per-share basis. Moreover, it recorded a substantial revenue of $1,978,214,000.00 underscoring its strong market presence. The stock is affordable at $47.85 making it an attractive option for budget-conscious investors. With an average trading volume of 1,409,103.00 the stock demonstrates moderate liquidity, appealing to a range of investors. Holding a mid-range market capitalization of $10,362,204,600.00 the company positions itself as a steady performer within the competitive landscape. QIAGEN is a key player in the Medical - Diagnostics & Research industry, significantly contributing to the overall market dynamics and advancements. It belongs to the Healthcare sector, where it drives innovation and fosters growth, reinforcing its role as a leader in molecular diagnostics and related fields.
Investing in Qiagen N.V. (QGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Qiagen N.V. stock to fluctuate between $37.63 (low) and $48.82 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-08, Qiagen N.V.'s market cap is $10,362,204,600, based on 216,556,000 outstanding shares.
Compared to Eli Lilly & Co., Qiagen N.V. has a Lower Market-Cap, indicating a difference in performance.
Qiagen N.V. pays dividends. The current dividend yield is 6.03%, with a payout of $1.26 per share.
To buy Qiagen N.V. (QGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QGEN. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Qiagen N.V.'s last stock split was 35:36 on 2025-01-29.
Revenue: $1,978,214,000 | EPS: $0.37 | Growth: -75.97%.
Visit https://www.qiagen.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $62.56 (2021-02-08) | All-time low: $36.84 (2023-10-30).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to release results for Q2 2025 and hold webcast.
businesswire.com
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a.
zacks.com
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
marketwatch.com
The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.
zacks.com
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
zacks.com
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
zacks.com
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
See all news